Maxim Group set a $4.00 price target on AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) in a report published on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
AEZS has been the subject of a number of other research reports. Zacks Investment Research cut shares of AEterna Zentaris from a hold rating to a sell rating in a research report on Friday, May 12th. HC Wainwright decreased their target price on shares of AEterna Zentaris from $7.50 to $3.00 and set a buy rating for the company in a research report on Wednesday, May 10th.
Shares of AEterna Zentaris (NASDAQ:AEZS) traded up 17.92% during midday trading on Friday, hitting $2.04. 4,478,036 shares of the company traded hands. AEterna Zentaris has a 52 week low of $0.78 and a 52 week high of $5.59. The stock’s market capitalization is $29.24 million. The company has a 50-day moving average price of $1.56 and a 200-day moving average price of $2.08.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.05. AEterna Zentaris had a negative return on equity of 502.76% and a negative net margin of 1,945.78%. The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.22 million. The firm’s revenue was up 153.1% on a year-over-year basis. Analysts anticipate that AEterna Zentaris will post ($1.36) earnings per share for the current fiscal year.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.